drugset / Trial / NCT00651937

Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom Burden

NCT00651937

Phase 2 Completed 80 enrolled M.D. Anderson Cancer Center
RandomizedParallel-groupOpen-labelTreatment

Summary

The goal of this clinical research study is to learn whether higher doses of stem cells can help to decrease the symptoms that occur after melphalan. Another goal of the study is to see how the dose of infused stem cells affects the levels of certain proteins in your blood. Researchers also want to learn how the dose of stem cells that you receive affects the quality of your life during the weeks after the transplant procedure.

Timeline

Start
2008-03
Primary completion
2016-01
Completion
2016-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Granulocyte colony-stimulating factor Protein / enzyme biologic 5 ug/kg Subcutaneous
Comparator Melphalan Small molecule 100 mg/m2 Intravenous